BR112023022584A2 - Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada - Google Patents

Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada

Info

Publication number
BR112023022584A2
BR112023022584A2 BR112023022584A BR112023022584A BR112023022584A2 BR 112023022584 A2 BR112023022584 A2 BR 112023022584A2 BR 112023022584 A BR112023022584 A BR 112023022584A BR 112023022584 A BR112023022584 A BR 112023022584A BR 112023022584 A2 BR112023022584 A2 BR 112023022584A2
Authority
BR
Brazil
Prior art keywords
domain variants
receptors
variant
thermal stability
improved thermal
Prior art date
Application number
BR112023022584A
Other languages
English (en)
Portuguese (pt)
Inventor
Alessandro Masiero
Bodo Tillmann
Béatrice Cameron
Christian Lange
Ingo Focken
Jochen Beninga
Sagar Kathuria
Sunghae Park
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112023022584A2 publication Critical patent/BR112023022584A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112023022584A 2021-05-27 2022-05-27 Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada BR112023022584A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193665P 2021-05-27 2021-05-27
EP21315127 2021-07-15
PCT/IB2022/055019 WO2022249146A1 (en) 2021-05-27 2022-05-27 Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY

Publications (1)

Publication Number Publication Date
BR112023022584A2 true BR112023022584A2 (pt) 2024-01-09

Family

ID=82358573

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022584A BR112023022584A2 (pt) 2021-05-27 2022-05-27 Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada

Country Status (12)

Country Link
US (2) US12297273B2 (https=)
EP (1) EP4347640A1 (https=)
JP (1) JP2024522092A (https=)
KR (1) KR20240015093A (https=)
AU (1) AU2022282666A1 (https=)
BR (1) BR112023022584A2 (https=)
CA (1) CA3216005A1 (https=)
CO (1) CO2023016432A2 (https=)
IL (1) IL308733A (https=)
MX (1) MX2023014100A (https=)
TW (1) TW202306584A (https=)
WO (1) WO2022249146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7312181B2 (en) 2005-04-08 2007-12-25 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP5898082B2 (ja) * 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2825557B1 (en) * 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EA201891753A1 (ru) * 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
AR108963A1 (es) 2016-04-13 2018-10-17 Merial Inc Dispositivo de inyección con mecanismo de accionamiento para administrar múltiples formulaciones líquidas, tales como vacunas
CN108218998A (zh) * 2017-12-31 2018-06-29 武汉班科生物技术股份有限公司 一种突变型人源IgG的Fc片段及其制备方法与应用
IL276286B2 (en) 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
JP7792330B2 (ja) * 2019-09-03 2025-12-25 アムジエン・インコーポレーテツド Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法

Also Published As

Publication number Publication date
AU2022282666A1 (en) 2024-01-18
IL308733A (en) 2024-01-01
CA3216005A1 (en) 2022-12-01
CO2023016432A2 (es) 2023-12-11
US20230077531A1 (en) 2023-03-16
MX2023014100A (es) 2023-12-11
US20250376526A1 (en) 2025-12-11
KR20240015093A (ko) 2024-02-02
TW202306584A (zh) 2023-02-16
US12297273B2 (en) 2025-05-13
WO2022249146A1 (en) 2022-12-01
JP2024522092A (ja) 2024-06-11
EP4347640A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
BR112021023048A2 (pt) Moléculas de ligação a cd19 e usos das mesmas
BRPI1008692B8 (pt) anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
BRPI0717768B8 (pt) anticorpo, epítopo, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
MX2010001481A (es) Proteasas fungales acidas.
BR112015022491A2 (pt) variantes de inibidor de tecido de metaloprotease tipo três (timp-3), ácido nucleico isolado, vetor de expressão, célula hospedeira isolada e método para produzir uma muteína de timp-3 recombinante, bem como composição e seu uso
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
BRPI0911385A2 (pt) mutantes fgf21 e seus usos
PE20170906A1 (es) Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados
ECSP088262A (es) Proteínas de fusión de albúmina
BR112013032764A2 (pt) misturador estático para tratamento de gases de exaustão e método de fabricação do mesmo
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BRPI0619595B8 (pt) anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
BRPI0801078A2 (pt) processo para relaxar ou alisar os cabelos
AR067830A1 (es) Proteinas streptococcus inmunogenicas
BR112015026707A2 (pt) Proteína ppr, e, complexo
BR112015019729A2 (pt) composição inibidora da il-1b e uso da mesma
BR112023003468A2 (pt) Variantes de uma xiloglucanase da família 44
BR112023022584A2 (pt) Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada
CL2024002358A1 (es) Variante de fitasa; método de producción; composición; y su uso.
MX2021015614A (es) Enzimas variantes de sacarosa fosforilasa modificadas geneticamente.
BR112018077225A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas